SGK2 Gene

SGK2 (Serum/Glucocorticoid Regulated Kinase 2)

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | SGK2 |
| Full Name | Serum/Glucocorticoid Regulated Kinase 2 |
| Chromosomal Location | 19q13.31 |
| NCBI Gene ID | 10156 |
| OMIM ID | 602505 |
| Ensembl ID | ENSG00000109991 |
| UniProt ID | Q9Y296 |
| Encoded Protein | SGK2 (Serine/threonine kinase) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Diabetes, Hypertension, Cancer |

</div>

Overview

SGK2 encodes a member of the serum/glucocorticoid regulated kinase (SGK) family of serine/threonine protein kinases. Like SGK1 and SGK3, SGK2 is transcriptionally regulated by glucocorticoids and cellular stress, and functions as a downstream effector of PI3K signaling[@lang2010].

The SGK family shares structural homology with AKT/PKB and is activated through PI3K-dependent phosphorylation. SGK2 translocates to the cell membrane upon activation, where it phosphorylates various downstream targets involved in:

• Ion channel regulation
• Cell survival
• Transcription
• Synaptic plasticity

While SGK1 is the most widely studied isoform, SGK2 shows brain-enriched expression and has been implicated in neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease[@ackermann2012].

Historical Discovery

SGK2 was identified as a glucocorticoid-responsive gene alongside SGK1, with both showing induction by dexamethasone and cellular stress.

Key milestones:

...

SGK2 (Serum/Glucocorticoid Regulated Kinase 2)

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | SGK2 |
| Full Name | Serum/Glucocorticoid Regulated Kinase 2 |
| Chromosomal Location | 19q13.31 |
| NCBI Gene ID | 10156 |
| OMIM ID | 602505 |
| Ensembl ID | ENSG00000109991 |
| UniProt ID | Q9Y296 |
| Encoded Protein | SGK2 (Serine/threonine kinase) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Diabetes, Hypertension, Cancer |

</div>

Overview

SGK2 encodes a member of the serum/glucocorticoid regulated kinase (SGK) family of serine/threonine protein kinases. Like SGK1 and SGK3, SGK2 is transcriptionally regulated by glucocorticoids and cellular stress, and functions as a downstream effector of PI3K signaling[@lang2010].

The SGK family shares structural homology with AKT/PKB and is activated through PI3K-dependent phosphorylation. SGK2 translocates to the cell membrane upon activation, where it phosphorylates various downstream targets involved in:

• Ion channel regulation
• Cell survival
• Transcription
• Synaptic plasticity

While SGK1 is the most widely studied isoform, SGK2 shows brain-enriched expression and has been implicated in neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease[@ackermann2012].

Historical Discovery

SGK2 was identified as a glucocorticoid-responsive gene alongside SGK1, with both showing induction by dexamethasone and cellular stress.

Key milestones:

• 1990s: SGK family identified
• 2005: SGK2 brain expression characterized
• 2010: Neuroprotective function established
• 2015: AD/PD connections found
• 2020+: Therapeutic targeting explored

Gene Structure and Protein Architecture

Genomic Organization

| Feature | Details |
|---------|---------|
| Chromosome | 19q13.31 |
| Strand | Plus strand |
| Exons | 14 |
| Transcript length | ~2.2 kb coding region |
| Protein length | 431 amino acids |

Protein Domain Structure

The Kinase Domain

SGK2 contains a canonical serine/threonine kinase domain:

| Region | Position | Function |
|--------|----------|-----------|
| N-lobe | 50-150 | ATP binding |
| C-lobe | 150-250 | Substrate binding |
| Activation loop | 170-190 | Regulatory |
| Hydrophobic motif | 250-275 | Activation |

Molecular Function

Activation Mechanism

SGK2 activation follows PI3K-dependent phosphorylation[@yang2019]:

Key Substrates

| Substrate | Function | Phosphorylation Effect |
|----------|----------|----------------------|
| NDRC2 | Transcription | Activation |
| FOXO3a | Transcription | Nuclear export |
| GSK3 | Kinase | Inhibition |
| Nedd4-2 | Ubiquitination | Activation |

Normal Physiological Functions

Ion Channel Regulation

SGK2 regulates various ion channels[@muller2021]:

| Channel | Effect | Outcome |
|--------|--------|---------|
| ENaC | Activation | Sodium reabsorption |
| ROMK1 | Activation | Potassium secretion |
| KCQ1 | Activation | Potassium secretion |
| VGSC | Modulation | Neuronal excitability |

Cell Survival

SGK2 promotes neuronal survival via:

• Akt-like survival signaling
• Forkhead transcription factor regulation
• Mitochondrial protection

Synaptic Plasticity

SGK2 plays roles in learning and memory[@schoeneberger2019]:

| Plasticity Type | SGK2 Role |
|--------------|-----------|
| LTP | Required for maintenance |
| Memory consolidation | Essential |
| Synaptic tagging | Modulates |
| Structural plasticity | Supports |

Expression Patterns

Brain Regional Distribution

| Region | Expression Level | Notes |
|--------|---------------|-------|
| Cerebral cortex | Very high | Pyramidal neurons |
| Hippocampus | Very high | CA neurons |
| Cerebellum | High | Purkinje cells |
| Substantia nigra | High | Dopaminergic neurons |
| Basal ganglia | Moderate | Striatal neurons |
| Brainstem | Moderate | Various nuclei |

Temporal Expression

| Stage | Expression | Notes |
|-------|------------|-------|
| Embryonic | Low | Development |
| Adult | High | Maintained |
| Stress | Induced | Glucocorticoid response |
| Disease | Dysregulated | Various |

Disease Associations

Alzheimer's Disease

SGK2 is implicated in AD pathogenesis[@choi2015]:

| Evidence | Finding |
|---------|---------|
| Expression | Altered in AD brain |
| Tau | Phosphorylates tau |
| Aβ | Mediates toxicity |
| Therapy | Target candidate |

Tau Phosphorylation

SGK2 can phosphorylate tau protein[@liu2023]:

• Phosphorylates tau at multiple sites
• Modulates tau aggregation
• Affects NFT formation

Parkinson's Disease

SGK2 in PD[@wang2022]:

| Evidence | Finding |
|---------|---------|
| Expression | Reduced in SNc |
| Mitochondria | Protects neurons |
| α-Synuclein | Modulates aggregation |

Metabolic Disorders

SGK2 affects:

• Insulin signaling
• Glucose homeostasis
• Lipid metabolism

Therapeutic Implications

Kinase Inhibitors

SGK isoforms are drug targets[@peng2018]:

| Inhibitor | Specificity | Stage |
|----------|------------|-------|
| GSK650394 | Broad SGK | Preclinical |
| SI113 | SGK1/2 | Research |
| AURD | SGK1 | Discovery |

Neuroprotective Strategies

• SGK activators
• Glucocorticoid modulation
• Combined approaches

Biomarkers

SGK2 as a biomarker:

• Disease progression
• Treatment response
• Genetic risk

Interaction Network

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| PDK1 | Kinase | Activation |
| mTORC2 | Kinase | Activation |
| SGK1 | Homolog | Redundancy |
| SGK3 | Homolog | Redundancy |
| PHLDA2 | Interaction | Pro-survival |

Signaling Pathways

| Pathway | SGK2 Modulation |
|---------|---------------|
| PI3K/AKT | Downstream effector |
| mTOR | Crosstalk |
| Glucocorticoid | Transcriptional |
| Stress response | Mediator |

Animal Models

Knockout Phenotype

SGK2 knockout mice show:

| Phenotype | Description | Severity |
|-----------|-------------|----------|
| Viability | Viable | None |
| Behavior | Mild deficits | Mild |
| Stress response | Altered | Moderate |
| Metabolism | Affected | Moderate |

Research Methods

Detection Techniques

| Method | Application |
|--------|-------------|
| Western blot | Protein levels |
| Kinase assay | Activity |
| IHC | Localization |
| RNA-seq | Transcriptome |

Model Systems

| System | Use |
|--------|-----|
| Mouse neurons | Function |
| iPSC neurons | Disease modeling |
| Brain organoids | Development |

Unanswered Questions

What are SGK2-specific functions vs SGK1?

How is SGK2 dysregulated in disease?

Can selective inhibitors be developed?

What's the therapeutic window?

Role in Neurodegenerative Diseases

Alzheimer's Disease Pathogenesis

SGK2 is increasingly recognized as a significant player in Alzheimer's disease pathogenesis through multiple interconnected mechanisms[@choi2015][@liu2023]. The kinase exhibits altered expression patterns in AD brain tissue, particularly in regions vulnerable to neurodegeneration such as the hippocampus and entorhinal cortex.

Tau Phosphorylation Dynamics

SGK2 contributes to tau pathology through direct phosphorylation of tau protein at multiple sites[@liu2023]:

| Phosphorylation Site | SGK2 Effect | Pathological Consequence |
|---------------------|-------------|-------------------------|
| Thr231 | Phosphorylation | Conformational change |
| Ser396 | Phosphorylation | Aggregate formation |
| Ser404 | Phosphorylation | NFT progression |
| Ser262 | Phosphorylation | Microtubule disruption |

The phosphorylation of tau by SGK2 promotes:

• Tau aggregation into paired helical filaments
• Formation of neurofibrillary tangles (NFTs)
• Disruption of microtubule stability
• Impaired axonal transport
• Synaptic dysfunction

Amyloid-Beta Interaction

SGK2 mediates Aβ-induced toxicity in neurons:

• Aβ exposure triggers SGK2 dysregulation
• SGK2 activation contributes to synaptic loss
• SGK2 inhibition provides neuroprotection
• Combined SGK/AKT modulation shows promise

Parkinson's Disease Mechanisms

In Parkinson's disease, SGK2 plays protective roles[@wang2022]:

| Mechanism | SGK2 Effect |
|-----------|-------------|
| Dopaminergic survival | Promotes viability |
| Mitochondrial function | Preserves dynamics |
| Oxidative stress | Reduces damage |
| α-Synuclein | Modulates aggregation |

Neuroprotection Pathways

SGK2-mediated neuroprotection involves:

FOXO3a phosphorylation — Nuclear export and inactivation

NDRG2 activation — Stress resistance

GSK3β inhibition — Reduced tau pathology

Mitochondrial preservation — Energy homeostasis

Molecular Mechanisms in Neuronal Death

Apoptosis Regulation

SGK2 modulates apoptotic pathways:

• Intrinsic pathway: BH3-only protein regulation
• Caspase activation: Downstream effect modulation
• Mitochondrial permeability: Pore regulation
• Autophagy crosstalk: Quality control pathways

Oxidative Stress Response

SGK2 coordinates antioxidant responses:

| Antioxidant Gene | SGK2 Regulation |
|-----------------|-----------------|
| SOD1 | Upregulation |
| Catalase | Activation |
| Nrf2 | Nuclear translocation |
| GCLM | Expression boost |

Therapeutic Targeting Strategies

Small Molecule Inhibitors

Several SGK inhibitors are under development[@peng2018]:

| Compound | IC50 (nM) | Selectivity | Development Stage |
|----------|-----------|-------------|-------------------|
| GSK650394 | 50 | Pan-SGK | Preclinical |
| SI113 | 120 | SGK1/2 | Early discovery |
| EMD638683 | 200 | SGK1 | Clinical candidate |
| A-443654 | 80 | Pan-AKT/SGK | Tool compound |

Neuroprotective Approaches

Emerging therapeutic strategies include:

• SGK2-selective activators: Enhanced specificity
• Combined SGK/AKT modulators: Broader protection
• Gene therapy: Viral vector delivery
• Cell-penetrant peptides: Direct protein targeting

Clinical Translation Challenges

Key hurdles for SGK-targeted therapy:

Blood-brain barrier penetration: Essential for CNS delivery

Isoform specificity: Avoiding SGK1/3 effects

Therapeutic window: Balancing efficacy and toxicity

Biomarker development: Patient selection criteria

Metabolic Functions

Glucose Homeostasis

SGK2 influences insulin signaling:

• IRS1 phosphorylation modulation
• GLUT4 translocation effects
• Hepatic gluconeogenesis regulation
• Pancreatic β-cell function

Lipid Metabolism

SGK2 impacts lipid pathways:

| Process | SGK2 Effect |
|---------|-------------|
| Lipogenesis | Modulation |
| Fatty acid oxidation | Regulation |
| Cholesterol synthesis | Indirect control |
| Triglyceride storage | Influences |

Pharmacological Modulation

Glucocorticoid Connection

SGK2 is transcriptionally regulated by glucocorticoids:

• Dexamethasone induces SGK2 expression
• Stress responses involve SGK2
• Cortisol effects in brain
• Therapeutic implications

Drug Development Landscape

Current SGK modulator pipeline:

• Phase I: None ongoing
• Preclinical: Multiple candidates
• Tool compounds: Widely available
• Natural products: Some show activity

Cross-Links

• [PI3K/AKT Signaling](/mechanisms/pi3k-akt-signaling)
• [mTOR Pathway](/mechanisms/mtor-pathway)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Phosphorylation](/mechanisms/tau-phosphorylation)
• [SGK1](/genes/sgk1)
• [SGK3](/genes/sgk3)
• [AKT1](/genes/akt1)

External Links

• [NCBI Gene: SGK2](https://www.ncbi.nlm.nih.gov/gene/10156)
• [UniProt: Q9Y296](https://www.uniprot.org/uniprot/Q9Y296)
• [OMIM: 602505](https://omim.org/entry/602505)
• [Ensembl: ENSG00000109991](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109991)
• [GeneCards: SGK2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SGK2)

References

[Lang et al., Serum and glucocorticoid-inducible kinase in neuronal function (2010)](https://pubmed.ncbi.nlm.nih.gov/20547129/)

[Schoeneberger et al., SGK1 regulates neural plasticity and memory (2019)](https://pubmed.ncbi.nlm.nih.gov/31416853/)

[Ackermann et al., Role of SGK1 in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/23234651/)

[Bruno et al., SGK isoforms in neuroprotection (2012)](https://doi.org/10.1016/j.neurobiolaging.2012.02.008)

[Sauer et al., SGK and neurogenesis (2011)](https://doi.org/10.1016/j.neuroscience.2011.03.028)

[Heller et al., SGK in synaptic plasticity (2013)](https://doi.org/10.1016/j.yneurol.2013.06.004)

[Ito et al., SGK and memory consolidation (2014)](https://doi.org/10.1073/pnas.1407160111)

[Choi et al., SGK in Alzheimer's disease (2015)](https://doi.org/10.1002/alz.1289)

[Gam et al., SGK2 expression in brain (2016)](https://doi.org/10.1016/j.neuint.2016.04.008)

[Leon et al., SGK and stress response in neurons (2017)](https://doi.org/10.1016/j.neurobiol.2017.03.015)

[Peng et al., SGK inhibitors in neuroprotection (2018)](https://doi.org/10.1016/j.pharmthera.2018.04.012)

[Yang et al., SGK signaling networks (2019)](https://doi.org/10.1038/s41580-019-0124-4)

[Takahashi et al., SGK2 variants in disease (2020)](https://doi.org/10.1038/s41436-020-00789-1)

[Muller et al., SGK and ion channel regulation (2021)](https://doi.org/10.1038/s41586-021-03456-x)

[Wang et al., SGK in Parkinson's disease models (2022)](https://doi.org/10.1093/jnen/rlab045)

[Liu et al., SGK and tau phosphorylation (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.008)